A 'previously overlooked' variant of a common protein may hold the key to augmenting the effectiveness of breast cancer treatment, according to a new study from the University of Manchester.
However the uncommon RAC1B, the only known alternatively spliced variant of the small GTPase RAC1, is particularly important in cancer and has previously been shown to be an important mediator of colorectal tumourigenesis. Using genetically engineered mouse models, they showed that in HER2/Neu-driven mammary tumours, RAC1B was expressed by a substantial subset of BCSCs, which required RAC1B function for their sustension and activity. Furthermore, when the team transplanted breast cancer cells into the mice, they found that the cancer cells lacking RAC1B formed no visible tumours, even after 100 days.
However, development of BCSC-targeting therapies has been held back by their heterogeneity and the lack of BCSC-selective molecular targets. "Our data suggest that RAC1B is a clinically relevant molecular target for the development of BCSC-targeting therapies that may improve the effectiveness of doxorubicin-mediated chemotherapy," the authors concluded.
may be you want to say 'boosters'? LOL!
Health Health Latest News, Health Health Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Source: clevelanddotcom - 🏆 301. / 63 Read more »
Source: SciTechDaily1 - 🏆 84. / 68 Read more »